<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: government", fill: "#c23b22"},
{source: "1: government", target: "5: public policy spending", fill: "#cc4e5c"},
{source: "5: public policy spending", target: "5: provisions available resources", fill: "#cc4e5c"},
{source: "5: provisions available resources", target: "5: economic cycles", fill: "#cc4e5c"},
{source: "5: economic cycles", target: "5: significant", fill: "#cc4e5c"},
{source: "5: significant", target: "5: capital spending policies", fill: "#cc4e5c"},
{source: "5: public policy spending", target: "6: significant", fill: "#808080"},
{source: "6: significant", target: "6: products which would", fill: "#808080"},
{source: "6: products which would", target: "6: operations", fill: "#808080"},
{source: "6: significant", target: "8: thirdparty", fill: "#ffddf4"},
{source: "8: thirdparty", target: "8: reimbursement", fill: "#ffddf4"},
{source: "8: reimbursement", target: "8: acceptance", fill: "#ffddf4"},
{source: "8: thirdparty", target: "13: Governments ", fill: "#321414"},
{source: "13: Governments ", target: "13: incorporating", fill: "#321414"},
{source: "13: incorporating", target: "13: technologies", fill: "#321414"},
{source: "13: technologies", target: "13: such products", fill: "#321414"},
{source: "13: such products", target: "13: appropriate level", fill: "#321414"},
{source: "13: appropriate level", target: "13: reimbursement", fill: "#321414"},
{source: "13: Governments ", target: "18: addition through", fill: "#8b0000"},
{source: "18: addition through", target: "18: purchasing power", fill: "#8b0000"},
{source: "18: purchasing power", target: "18: payors often seek discounts price reductions", fill: "#8b0000"},
{source: "18: payors often seek discounts price reductions", target: "18: incentives from medical products suppliers", fill: "#8b0000"},
{source: "18: addition through", target: "23: bringing new products", fill: "#fafad2"},
{source: "23: bringing new products", target: "23: market uncertainties", fill: "#fafad2"},
{source: "23: market uncertainties", target: "23: future healthcare policy legislation", fill: "#fafad2"},
{source: "23: future healthcare policy legislation", target: "23: regulations as well as", fill: "#fafad2"},
{source: "23: regulations as well as", target: "23: private market practices could materially affect", fill: "#fafad2"},
{source: "23: private market practices could materially affect", target: "23: commercially", fill: "#fafad2"},
{source: "23: commercially", target: "23: quantities at profitable prices", fill: "#fafad2"},
{source: "23: bringing new products", target: "24: additional capital", fill: "#ffef00"},
{source: "24: additional capital", target: "24: acquisitions", fill: "#ffef00"},
{source: "24: acquisitions", target: "24: development", fill: "#ffef00"},
{source: "24: development", target: "24: new products", fill: "#ffef00"},
{source: "24: additional capital", target: "36: aggressive competition", fill: "#0087bd"},
{source: "36: aggressive competition", target: "36: compete effectively", fill: "#0087bd"},
{source: "36: aggressive competition", target: "60: distributor", fill: "#c33"},
{source: "60: distributor", target: "60: materially adversely affect", fill: "#c33"},
{source: "60: materially adversely affect", target: "60: such as manufacturing", fill: "#c33"},
{source: "60: such as manufacturing", target: "60: selling competing", fill: "#c33"},
{source: "60: distributor", target: "96: regulatory", fill: "#f88379"},
{source: "96: regulatory", target: "96: manufacturing", fill: "#f88379"},
{source: "96: manufacturing", target: "96: operations", fill: "#f88379"},
{source: "96: regulatory", target: "100: necessary", fill: "#808080"},
{source: "100: necessary", target: "100: clearances", fill: "#808080"},
{source: "100: clearances", target: "100: manufacture", fill: "#808080"},
{source: "100: necessary", target: "123: dependent on", fill: "#de3163"},
{source: "123: dependent on", target: "123: key executives", fill: "#de3163"},
{source: "123: key executives", target: "123: technical staff", fill: "#de3163"},
{source: "123: technical staff", target: "123: key personnel", fill: "#de3163"},
{source: "123: key personnel", target: "123: attract additional qualified personnel could", fill: "#de3163"},
{source: "123: dependent on", target: "START_HERE", fill: "#de3163"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government">Government</a></td>
      <td>A government is the system or group of people governing an organized community, generally a state.\nIn the case of its broad associative definition, government normally consists of legislature, executive, and judiciary.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Government_of_India">Government of India</a></td>
      <td>The Government of India (ISO: Bhārat Sarkār) (often abbreviated as GoI; also known as the Central or Union Government), or simply the Centre, is the federal governing authority of the Republic of India created by the Constitution of India as the legislative, executive and judicial authority to govern the union of twenty eight states and eight union territories. The president acts as the head of state and is the highest figure of authority, nominally, of the nation however it is the prime minister who is the chief executive.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australian_Government">Australian Government</a></td>
      <td>The Australian Government, also known as the Commonwealth Government, is the national government of Australia, a federal parliamentary constitutional monarchy. Like other Westminster-style systems of government, the Australian Government is made up of three branches: the executive (the prime minister, the ministers, and government departments), the legislative (the Parliament of Australia), and the judicial.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_government_of_the_United_States">Federal government of the United States</a></td>
      <td>The federal government of the United States (U.S. federal government or U.S. government) is the national government of the United States, a federal republic in North America, composed of 50 states, a city within a federal district (the city of Washington in the District of Columbia, where the entire federal government is based), five major self-governing territories and several island possessions. The federal government is composed of three distinct branches: legislative, executive, and judicial, whose powers are vested by the U.S. Constitution in the Congress, the president and the federal courts, respectively.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Reimbursement">Reimbursement</a></td>
      <td>Reimbursement is the act of compensating someone for an out-of-pocket expense by giving them an amount of money equal to what was spent.Companies, governments and nonprofit organizations may compensate their employees or officers for necessary and reasonable expenses; under US\nlaw, these expenses may be deducted from taxes by the organization and treated as untaxed income for the recipient provided that accountability conditions are met. UK law provides for deductions for travel and subsistence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Capitation_(healthcare)">Capitation (healthcare)</a></td>
      <td>Capitation is a payment arrangement for health care service providers. It pays a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mergers_and_acquisitions">Mergers and acquisitions</a></td>
      <td>In corporate finance, mergers and acquisitions (M&amp;A) are transactions in which the ownership of companies, other business organizations, or their operating units are transferred or consolidated with other entities. As an aspect of strategic management, M&amp;A can allow enterprises to grow or downsize, and change the nature of their business or competitive position.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Knowledge_acquisition">Knowledge acquisition</a></td>
      <td>Knowledge acquisition is the process used to define the rules and ontologies required for a knowledge-based system. The phrase was first used in conjunction with expert systems to describe the initial tasks associated with developing an expert system, namely finding and interviewing domain experts and capturing their knowledge via rules, objects, and frame-based ontologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porcelain_manufacturing_companies_in_Europe">Porcelain manufacturing companies in Europe</a></td>
      <td>Porcelain manufacturing companies are firms which manufacture porcelain.\n\n\n== European porcelain manufacturers before the 18th century ==\nThe table below lists European manufacturers of porcelain established before the 18th century.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>VIASYS HEALTHCARE INC      Item 1A Risk Factors        Demand for some of our products depends on the <font color="blue">capital spending policies</font> of     our customers and on <font color="blue">government</font> funding policies</td>
    </tr>
    <tr>
      <td>Changes in these policies     could <font color="blue">negatively</font> affect our business</td>
    </tr>
    <tr>
      <td>We also sell to     laboratories, universities, healthcare providers and public and private     research  <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>Many factors, including <font color="blue">public policy spending</font>     provisions, available resources and <font color="blue">economic cycles</font> have a <font color="blue">significant</font>     effect on the <font color="blue">capital spending policies</font> of these entities</td>
    </tr>
    <tr>
      <td>These factors can     have a <font color="blue">significant</font> effect on the demand for our <font color="blue">products <font color="blue">which would</font></font> have an     adverse effect on our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>For example, a reduction in     funding  to  major <font color="blue">government</font> research supported agencies, such as the     National Institutes of Health or the National Science Foundation, could     <font color="blue"><font color="blue">materially adversely affect</font> sales</font> of our <font color="blue">sleep diagnostic testing equipment</font></td>
    </tr>
    <tr>
      <td>We  depend  on  third-party  <font color="blue">reimbursement</font> to our customers for market     <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">profitability would suffer</font> if third-party     payors  failed  to <font color="blue">provide <font color="blue">appropriate level</font>s</font> of <font color="blue">reimbursement</font> for the     purchase or use of our products or if any <font color="blue">government</font>al or third-party payor     were to issue an <font color="blue">adverse de<font color="blue">termination</font></font> or <font color="blue">restrictive coverage policy</font></td>
    </tr>
    <tr>
      <td>Sales of medical products largely depend on the <font color="blue">reimbursement</font> of     patients &amp;apos  medical expenses by <font color="blue">government</font> healthcare programs and private     health insurers</td>
    </tr>
    <tr>
      <td><font color="blue">Without     </font>both favorable <font color="blue"><font color="blue">coverage de<font color="blue">termination</font>s</font> by</font>, and the <font color="blue">financial support</font> of,     <font color="blue">government</font> and third-party insurers, the market for some of our products     could be limited</td>
    </tr>
    <tr>
      <td><font color="blue">Governments </font>and private insurers in many countries closely examine     medical products and devices <font color="blue">incorporating</font> new <font color="blue">technologies</font> to determine     whether to cover and reimburse for the purchase or use of <font color="blue">such products</font> and     devices and, if so, the <font color="blue">appropriate level</font> of <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>We cannot be     sure  that  third-party  <font color="blue">payors will cover</font> and <font color="blue">reimburse customers</font> for     purchases of <font color="blue">future products</font> or that any such <font color="blue">reimbursement</font> will enable us     to sell these <font color="blue">products at profitable prices</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot</font> be sure that     third-party payors will maintain the <font color="blue">current level</font> of <font color="blue">reimbursement</font> to     physicians and <font color="blue">medical centers</font> for use of our <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adverse     </font><font color="blue">coverage de<font color="blue">termination</font>s</font> or any reduction in the amount of this <font color="blue">reimbursement</font>     <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Third-party payors emphasize managed care, leading to the use of     cost-effective <font color="blue">medical devices</font> by healthcare providers</td>
    </tr>
    <tr>
      <td>In addition, through     their <font color="blue">purchasing power</font>, these payors often seek discounts, price reductions     or other <font color="blue">incentives from medical products suppliers</font></td>
    </tr>
    <tr>
      <td>The federal <font color="blue">government</font> and <font color="blue">private insurers continue</font> to consider     ways to change the manner in <font color="blue">which healthcare services</font> are provided and paid     for in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In the future, it is possible that the <font color="blue">government</font>     may institute price controls and further limits on <font color="blue">Medicare and Medicaid     </font>spending</td>
    </tr>
    <tr>
      <td>These controls and <font color="blue">limits could materially affect</font> the payments we     receive from sales of our products</td>
    </tr>
    <tr>
      <td>Internationally, medical <font color="blue">reimbursement</font>     systems vary <font color="blue">significant</font>ly, with some <font color="blue">medical centers</font> having fixed budgets,     <font color="blue">regardless</font> of the level of <font color="blue">patient treatment</font> and other countries requiring     <font color="blue">application</font> for, and approval of, <font color="blue">government</font> or third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Even  if  we succeed in <font color="blue">bringing <font color="blue">new products</font></font> to market, uncertainties     regarding future healthcare policy, legislation and <font color="blue">regulations</font>, as well as     private market practices, could materially affect our ability to sell our     products in <font color="blue">commercially</font> acceptable <font color="blue">quantities at profitable prices</font></td>
    </tr>
    <tr>
      <td>We may need <font color="blue"><font color="blue">additional</font> capital</font> to sustain and expand our business, including     <font color="blue"><font color="blue">acquisition</font>s</font> and the <font color="blue">development</font> of <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>As  of  <font color="blue">December </font>31, 2005, we had cash and <font color="blue">cash equivalents</font> of     dlra19dtta5 million and a dlra150dtta0 million revolving credit <font color="blue"><font color="blue">facility</font> under which</font> we     have dlra70dtta2 million outstanding, which includes dlra2dtta7 million of outstanding     <font color="blue">standby letters</font> of credit, and of which dlra79dtta8 million was available for     borrowing</td>
    </tr>
    <tr>
      <td>The revolving credit <font color="blue">facility</font> can be increased to dlra200dtta0 million     at our request</td>
    </tr>
    <tr>
      <td>Both cash and the credit <font color="blue">facility</font> may be used to fund the     expansion of our business, either through <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">development</font> of new     products</td>
    </tr>
    <tr>
      <td>Our  ability  to access the credit <font color="blue">facility</font> is <font color="blue">dependent on</font>     <font color="blue">complying with</font> the debt                                         20       _________________________________________________________________       covenants that are part of that <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>These covenants include a maximum     <font color="blue">leverage ratio</font> of debt to earnings before interest, taxes and <font color="blue">depreciation</font>     and <font color="blue">amortization</font> ( &amp;quote EBITDA &amp;quote ) of 3dtta0, a minimum ratio of EBITDA to interest     expense of 4dtta0, minimum <font color="blue">stockholders</font> &amp;apos  equity and maximum annual capital     <font color="blue">expenditures</font> of dlra30 million or 5prca of the Companyapstas <font color="blue">consolidated net assets</font></td>
    </tr>
    <tr>
      <td>While we were in <font color="blue">compliance with</font> the <font color="blue">debt covenants</font> in the <font color="blue">Facility </font>at     <font color="blue">December </font>31, 2005 and expect to be able to meet these <font color="blue">requirements</font> in the     future,  failure  to satisfy any of the <font color="blue">conditions would</font> require us to     <font color="blue">renegotiate</font> the <font color="blue">facility</font> on terms that may not be favorable or could require     us  to  repay  any <font color="blue">outstanding balance</font></td>
    </tr>
    <tr>
      <td>While we would attempt to find     <font color="blue">alternative</font>  sources  to  fund  our  <font color="blue">operations</font>  from  other financial     <font color="blue">institutions</font>, we <font color="blue">cannot assure</font> you that we would be successful, or if we     were  successful  that  the new credit would be on terms that would be     attractive to us in financing our business plans</td>
    </tr>
    <tr>
      <td>The credit <font color="blue">facility</font> is due     to expire on May 3, 2010</td>
    </tr>
    <tr>
      <td>In addition, we may need to <font color="blue">seek capital beyond</font> that available</td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>funds for these <font color="blue">purposes on terms</font> favorable to us, whether through     <font color="blue">additional</font> equity financing, debt financing or other sources, may not be     available  when  needed and, if consummated, may result in <font color="blue">significant</font>     dilution to existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">secure <font color="blue">additional</font></font>     funding when required, we may be required to delay, scale back, and/or     abandon  some  or  all of our product <font color="blue">development</font> programs or proposed     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We  face  <font color="blue">aggressive competition</font> in many areas of our business and our     business will be harmed if we fail to <font color="blue">compete effectively</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">products currently</font>     <font color="blue">compete favorably with respect</font> to these factors, we cannot give assurance     that  we can maintain our <font color="blue"><font color="blue">competitive</font> position against</font> our current and     <font color="blue">potential <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>Many of our current and <font color="blue">potential <font color="blue">competitors</font></font> have     longer operating histories, greater name <font color="blue">recognition</font> and <font color="blue">substantially</font>     greater financial, technical and marketing resources than we have</td>
    </tr>
    <tr>
      <td>We may     not  be  able to <font color="blue">compete effectively</font> with these <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>To remain     <font color="blue">competitive</font>, we must develop <font color="blue">new products</font> and <font color="blue">periodically enhance</font> our     <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>We anticipate that we may have to adjust the prices of     many of our products to stay <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>In addition, new <font color="blue">competitors</font> may     emerge and <font color="blue">entire <font color="blue">product lines</font> may</font> be threatened by new <font color="blue">technologies</font> or     <font color="blue">market trends</font> that reduce the value of these <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>A  <font color="blue">significant</font> percentage of our total assets consist of <font color="blue">goodwill from</font>     acquired companies and we may be unable to realize the value of this asset</td>
    </tr>
    <tr>
      <td>We have acquired <font color="blue">significant</font> intangible assets, including     approximately dlra261dtta9 million of cost in excess of net assets of acquired     companies, or goodwill, recorded on our <font color="blue">balance sheet as</font> of <font color="blue">December </font>31,     2005</td>
    </tr>
    <tr>
      <td>This represents approximately 40prca of our <font color="blue">total assets as</font> of that date</td>
    </tr>
    <tr>
      <td>Our ability to realize the value of this <font color="blue">asset will depend on future cash</font>     flows of the acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Cash flow, in turn, <font color="blue">depends on how well</font> we     have  identified  these  acquired  <font color="blue">businesses</font> as desirable <font color="blue">acquisition</font>     candidates and how well we can integrate these acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We  may  incur  a variety of costs to engage in future <font color="blue"><font color="blue">acquisition</font>s</font> of     companies, products or <font color="blue">technologies</font>, and the anticipated benefits of those     <font color="blue"><font color="blue">acquisition</font>s</font> may never be realized</td>
    </tr>
    <tr>
      <td>As a part of our strategy to grow our business, we seek to make     strategic <font color="blue"><font color="blue">acquisition</font>s</font> of, or <font color="blue">significant</font> <font color="blue">investments</font> in, <font color="blue">complementary</font>     companies, products or <font color="blue">technologies</font>, although no <font color="blue">significant</font> <font color="blue">acquisition</font> or     <font color="blue">investments</font> are <font color="blue">currently pending</font></td>
    </tr>
    <tr>
      <td>We may not be successful in the future in     identifying companies that <font color="blue">meet out <font color="blue">acquisition</font> criteria</font></td>
    </tr>
    <tr>
      <td>The failure to     identify <font color="blue">such companies may limit</font> the <font color="blue">rate at which</font> we are able to grow our     business</td>
    </tr>
    <tr>
      <td>Furthermore, any future <font color="blue"><font color="blue">acquisition</font>s</font> that we do undertake could be     <font color="blue">accompanied</font> by risks such as:          •                 <font color="blue">Difficulties </font>in <font color="blue">integrating</font> the <font color="blue">operations</font> and personnel of                 acquired companies;                                         21       _________________________________________________________________       •            <font color="blue">Diversion  </font>of  our managementapstas <font color="blue">attention from</font> ongoing business            concerns;     •            Our <font color="blue">potential inability</font> to maximize our financial and strategic            <font color="blue">position through</font> the <font color="blue">successful in<font color="blue">corporation</font></font> of acquired <font color="blue">technology</font>            and <font color="blue">rights into</font> our products and services;     •            <font color="blue">Additional </font>expense associated with <font color="blue">amortization</font> of acquired assets;     •            Maintenance of uniform standards, controls, procedures and policies;            and     •            Impairment of existing relationships with employees, suppliers and            customers as a result of the <font color="blue">integration</font> of <font color="blue">new management personnel</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that we will be able to <font color="blue"><font color="blue">successfully</font> integrate</font>     any business, products, <font color="blue">technologies</font> or personnel that we might acquire in     the future, and our failure to do so <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>revenues account for a substantial portion of our     revenues</td>
    </tr>
    <tr>
      <td><font color="blue">International </font>revenues from continuing <font color="blue">operations</font>, including     <font color="blue">export revenues from</font> the <font color="blue">United States</font>, accounted for 43prca of our total     revenues in 2005 and 44prca of our <font color="blue">total revenues</font> in 2004</td>
    </tr>
    <tr>
      <td>While we plan to     <font color="blue">continue expanding</font> our presence in <font color="blue">international</font> markets, our <font color="blue">international</font>     <font color="blue">operations</font> present a number of risks, including the following:          •                 Foreign laws in a number of <font color="blue"><font color="blue">countries may</font> limit</font> our ability to                 properly maintain our <font color="blue">distribution channels</font></td>
    </tr>
    <tr>
      <td>For example, a                 number of foreign laws restrict our ability to terminate a                 <font color="blue">distributor</font> for taking actions that <font color="blue">materially adversely affect</font>                 our  business, <font color="blue">such as <font color="blue">manufacturing</font></font> and <font color="blue">selling competing</font>                 products</td>
    </tr>
    <tr>
      <td>•                 The <font color="blue">successful marketing</font> of our products in some countries,                 including many European countries, may require us to establish a                 <font color="blue">local presence</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">revenues generated</font> in these <font color="blue">countries may</font>                 not justify the expense of <font color="blue">establishing</font> and maintaining such a                 <font color="blue">local presence</font></td>
    </tr>
    <tr>
      <td>•                 <font color="blue">Fluctuations </font>in currency exchange rates have <font color="blue">occasionally</font> forced                 us to lower our prices, thereby reducing our margins for some of                 our <font color="blue">respiratory</font> and <font color="blue">neurodiagnostic</font> products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">competitive</font>  position  is  partially  <font color="blue">dependent on</font> protecting our     <font color="blue">intellectual property</font>, which can be <font color="blue">difficult</font> and expensive</td>
    </tr>
    <tr>
      <td>We believe that the success of our business depends, in part, on     obtaining <font color="blue">patent protection</font> for our products, defending our <font color="blue">patents once</font>     obtained  and  preserving  our  <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Patent and trade secret     protection  is  important  to  us because developing and marketing new     <font color="blue">technologies</font> and products is time consuming and expensive</td>
    </tr>
    <tr>
      <td>We own many US     and foreign patents and intend to apply for <font color="blue">additional</font> patents to cover our     products</td>
    </tr>
    <tr>
      <td>We may not receive <font color="blue">enforceable patents from</font> any pending or future     patent <font color="blue">application</font>s owned by or licensed to us</td>
    </tr>
    <tr>
      <td>The claims <font color="blue">allowed under</font> any     <font color="blue">issued patents may</font> not be <font color="blue">broad enough</font> to protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitive</font> position is <font color="blue">also dependent upon unpatented trade</font>     secrets</td>
    </tr>
    <tr>
      <td>Trade  secrets are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may     <font color="blue">independently</font>  develop <font color="blue">proprietary</font> information and <font color="blue">techniques</font> that are     <font color="blue">substantially</font> equivalent to ours or <font color="blue">otherwise gain access</font> to our trade     secrets, such as through unauthorized or <font color="blue">inadvertent disclosure</font> of our trade     secrets</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font> to enforce our <font color="blue">intellectual property</font>     rights, to protect our <font color="blue">trade secrets</font> and to determine the validity and scope     of  our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">litigation</font> could</font> result in substantial     expense and diversion of <font color="blue">attention from</font> our business and may not <font color="blue">adequately</font>     protect our <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>In addition, we may be <font color="blue">sued by <font color="blue">third parties</font></font> claiming that our     <font color="blue">products infringe on</font> the <font color="blue">intellectual property</font> rights of others</td>
    </tr>
    <tr>
      <td>This risk     is <font color="blue">exacerbated by</font> the fact that the validity and breadth of claims covered     in medical <font color="blue">technology</font> patents involve complex legal and factual questions     for <font color="blue">which important legal principles</font> are unresolved</td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> or     claims against us, whether or not valid, could result in                                         22       _________________________________________________________________       substantial costs, place a <font color="blue">significant</font> strain on our <font color="blue">financial resources</font>,     <font color="blue">divert management resources</font> and harm our reputation</td>
    </tr>
    <tr>
      <td>Such claims could     result in awards of substantial damages, which could have a material adverse     impact  on  our  operating results</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">intellectual property</font>     <font color="blue">litigation</font> or claims <font color="blue">could force us</font> to:          •                 cease selling, <font color="blue">incorporating</font> or using any of our products that                 <font color="blue">incorporate</font> the challenged <font color="blue">intellectual property</font>, <font color="blue">which would</font>                 <font color="blue">materially adversely affect</font> our revenue;          •                 obtain a <font color="blue">license from</font> the holder of the <font color="blue">infringed intellectual</font>                 property right, <font color="blue">which license may</font> not be <font color="blue">available on reasonable</font>                 terms, if at all; or          •                 redesign our products, <font color="blue">which would</font> be costly and time-consuming</td>
    </tr>
    <tr>
      <td>We are involved on an <font color="blue">ongoing basis</font> in claims and lawsuits relating to our     <font color="blue">operations</font>, including <font color="blue">product liability</font>, patent infringement, employment,     business  practices,  commercial <font color="blue"><font color="blue">transaction</font>s</font>, environmental and other     matters</td>
    </tr>
    <tr>
      <td>We are involved in the design, <font color="blue">manufacture</font> and sale of <font color="blue">health care</font>     products, which face an <font color="blue">inherent risk</font> of exposure to <font color="blue">product liability</font>     claims if our products are alleged to have caused injury or are found to be     unsuitable for their <font color="blue">intended use</font></td>
    </tr>
    <tr>
      <td>Any such claims could <font color="blue">negatively</font> impact     the sales of products that are the subject of such claims or other products</td>
    </tr>
    <tr>
      <td>Currently, we are a party to claims and lawsuits alleging that our products     have caused injury or death or are <font color="blue">otherwise unsuitable</font></td>
    </tr>
    <tr>
      <td>Moreover, we are     involved in <font color="blue">litigation</font> relating to patent infringement, employment, business     practices, commercial <font color="blue"><font color="blue">transaction</font>s</font>, environmental and other matters</td>
    </tr>
    <tr>
      <td>In addition, when we <font color="blue">enter into <font color="blue">new markets</font></font> or launch <font color="blue">new products</font>,     we may face <font color="blue">litigation</font> related to our <font color="blue">new products</font> and/or instituted by our     <font color="blue">competitors</font> in the <font color="blue">new markets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">ultimate outcome</font> of these <font color="blue">lawsuits cannot</font> be <font color="blue">predicted with</font>     <font color="blue">certainty</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> or claims against us, whether or not valid, could     result in substantial costs, place a <font color="blue">significant</font> strain on our financial     resources, <font color="blue">divert management resources</font> and harm our reputation</td>
    </tr>
    <tr>
      <td>While we     maintain  insurance  to  limit  our exposure to such claims, awards of     substantial damages in <font color="blue">connection with such</font> claims could have a material     <font color="blue">adverse impact on</font> our operating results and <font color="blue">financial conditions</font></td>
    </tr>
    <tr>
      <td>If we breach any of the <font color="blue">agreement</font>s under which we <font color="blue">license <font color="blue">commercialization</font></font>     rights to products or <font color="blue">technology</font> from others, we <font color="blue">could lose <font color="blue">license rights</font></font>     that are important to our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">license rights</font> to products and <font color="blue">technology</font> that are important to     our business and we expect to enter into <font color="blue">additional</font> licenses in the future</td>
    </tr>
    <tr>
      <td>Although the products and <font color="blue">technology</font> that we currently license account for     less than 5prca of our total annual revenues, we expect that this percentage     will increase as we develop and introduce <font color="blue">additional</font> licensed products to     the market</td>
    </tr>
    <tr>
      <td>For instance, a number of the therapy-based products that we are     developing <font color="blue">incorporate</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that we have <font color="blue">licensed from</font>     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Under these licenses, we are subject to <font color="blue">commercialization</font>,     <font color="blue">development</font>, sublicensing, royalty, insurance and other <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If we     fail to <font color="blue">comply with</font> any of these <font color="blue">requirements</font>, or <font color="blue">otherwise breach</font> a license     <font color="blue">agreement</font>, the <font color="blue">licensor may</font> have the right to terminate the license in whole     or to terminate the exclusive nature of the license</td>
    </tr>
    <tr>
      <td>In addition, upon the     <font color="blue">termination</font> of the license, we may be required to license to the licensor     any related <font color="blue">intellectual property</font> that we developed</td>
    </tr>
    <tr>
      <td>Our ability to market and sell our products depends upon receipt of domestic     and  foreign  <font color="blue">regulatory</font>  approval  of  our products and <font color="blue">manufacturing</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain or maintain <font color="blue">regulatory</font> approvals and     <font color="blue">compliance could</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">manufacturing</font> <font color="blue">operations</font> are subject to extensive     regulation  in  the <font color="blue">United States</font> by the FDA and by similar <font color="blue">regulatory</font>     agencies in many other countries in which we do business</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       The <font color="blue">principal risks</font> that we face in obtaining and maintaining the <font color="blue">regulatory</font>     approvals <font color="blue">necessary</font> to market our products include:          •                 The <font color="blue">approval process</font> for <font color="blue">medical devices</font> in the <font color="blue">United States</font>                 and abroad can be lengthy, expensive and require extensive                 preclinical and clinical trials</td>
    </tr>
    <tr>
      <td>As a result, we may expend                 substantial resources in developing and testing a new product                 but fail to obtain the <font color="blue">necessary</font> approvals or <font color="blue">clearances</font> to                 market or <font color="blue">manufacture</font> the product on a timely basis or at all</td>
    </tr>
    <tr>
      <td>•                 When we modify a medical device for which we have received                 <font color="blue">marketing approval</font>, we must determine whether the <font color="blue">modification</font>                 requires us to seek new <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>or                 other <font color="blue">regulatory</font> agency does not agree with our de<font color="blue">termination</font>,                 we may be prohibited from marketing the modified device until we                 receive the requisite <font color="blue">regulatory</font> approval or clearance</td>
    </tr>
    <tr>
      <td><font color="blue">In                 </font>addition, the FDA <font color="blue">actively enforces <font color="blue">regulations</font> prohibiting</font>                 marketing of devices for <font color="blue">indications</font> or uses that have not been                 cleared or <font color="blue">approved by</font> the FDA          •                 The FDA and foreign <font color="blue">regulatory</font> agencies require us to comply                 with an array of <font color="blue">manufacturing</font> and design controls and testing,                 quality control, storage and <font color="blue">documentation</font> procedures</td>
    </tr>
    <tr>
      <td><font color="blue">Because                 </font>our business is <font color="blue">geographically dispersed</font> in the <font color="blue">United States</font>                 and abroad, <font color="blue">compliance with</font> these procedures is <font color="blue">difficult</font> and                 costly</td>
    </tr>
    <tr>
      <td>If  we fail to <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, we could be     subject to a number of <font color="blue">enforcement actions</font>, including <font color="blue">warning letters</font>,     fines, product seizures, recalls, injunctions, total or <font color="blue">partial suspension</font>     of production, operating <font color="blue">restrictions</font> or limitations on marketing, refusal     of  the <font color="blue">government</font> to grant new <font color="blue">clearances</font> or approvals, withdrawal of     marketing  <font color="blue">clearances</font>  or  approvals and civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font><font color="blue">may also voluntarily conduct</font> a recall of a <font color="blue">problem product</font></td>
    </tr>
    <tr>
      <td>For a     summary  of  <font color="blue">government</font>  <font color="blue">regulations</font>  applicable  to our business, see      &amp;quote Business—Government Regulation &amp;quote</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">successfully</font> develop and/or commercialize our new and     <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>We have undertaken a substantial internal <font color="blue">development</font> strategy under     which  we  anticipate developing a number of therapy and service-based     products</td>
    </tr>
    <tr>
      <td>This <font color="blue">strategy represents</font> a <font color="blue">departure from</font> our traditional business     model and we may not have <font color="blue">sufficient expertise</font> and experience <font color="blue">necessary</font> to     <font color="blue">successfully</font> implement this <font color="blue">new strategy</font> and develop these <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Furthermore, the successful <font color="blue">development</font> and <font color="blue">commercialization</font> of these new     products will depend upon our ability to obtain <font color="blue">regulatory</font> approvals, as     discussed above</td>
    </tr>
    <tr>
      <td>If we are unable to obtain these <font color="blue">regulatory</font> approvals, we     will be unable to market and sell our products, which will <font color="blue">negatively</font> affect     our business</td>
    </tr>
    <tr>
      <td>Even if we are able to obtain <font color="blue">regulatory</font> approval for our     products we may have <font color="blue">difficult</font>y in bringing these products to market</td>
    </tr>
    <tr>
      <td>In     addition, once our <font color="blue">new products</font> are brought to market, their <font color="blue">shipment may</font> be     delayed  or  the <font color="blue">products may</font> have to be <font color="blue">discontinued based on design</font>,     mechanical, software, <font color="blue">regulatory</font> or other issues</td>
    </tr>
    <tr>
      <td>Finally, we may face     <font color="blue">competition from</font> other companies who may have a well-established presence in     the new market or a strong <font color="blue">intellectual property</font> position</td>
    </tr>
    <tr>
      <td>These <font color="blue">matters may</font>     <font color="blue">materially adversely affect</font> our business and reputation and may make us     unable to develop and/or commercialize <font color="blue">new products</font> in a <font color="blue">successful manner</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">dependence on suppliers</font> for <font color="blue">materials could impair</font> our ability to     <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td>Outside vendors, some of which are sole-source suppliers, provide     <font color="blue">key components</font> and <font color="blue">raw materials</font> that we use in the <font color="blue">manufacture</font> of our     products</td>
    </tr>
    <tr>
      <td>Although we believe that <font color="blue">alternative</font> sources for these components     and <font color="blue">raw materials</font> are available, any supply interruption in a limited or     sole-source component or raw material <font color="blue">could harm</font> our ability to <font color="blue">manufacture</font>     the <font color="blue"><font color="blue">affected product</font> until</font> we identify and qualify a new source of supply</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">uncorrected defect</font> or supplierapstas variation in a component or     raw material, <font color="blue">either unknown</font> to us or <font color="blue">incompatible with</font> our <font color="blue">manufacturing</font>     process, <font color="blue">could harm</font> our ability to <font color="blue">manufacture</font> the <font color="blue">affected product</font></td>
    </tr>
    <tr>
      <td>We may     not be able to find a qualified <font color="blue">alternative</font> supplier in a reasonable time     period, or on <font color="blue">commercially</font> reasonable terms, if at all, <font color="blue">which could impair</font>     our  ability to produce and supply our products</td>
    </tr>
    <tr>
      <td>If we cannot obtain a     <font color="blue">necessary</font>  component,  we may need to find, test and obtain <font color="blue">regulatory</font>     approval for a <font color="blue">replacement</font>                                         24       _________________________________________________________________       component, <font color="blue">which would</font> cause <font color="blue">significant</font> delays that could have a material     adverse effect on our business and operating results</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> our <font color="blue">key executives</font> and <font color="blue">technical staff</font>, and the loss of     <font color="blue">key personnel</font> or the failure to attract <font color="blue">additional</font> qualified personnel could     harm our business</td>
    </tr>
    <tr>
      <td>Our business is highly <font color="blue">dependent on</font> our <font color="blue">key executives</font> and technical     staff</td>
    </tr>
    <tr>
      <td>The  loss of <font color="blue">key personnel</font> or the failure to recruit <font color="blue">necessary</font>     <font color="blue">additional</font> or <font color="blue">replacement</font> personnel will likely impede the <font color="blue">achievement</font> of     our  business  <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>There is <font color="blue">intense competition</font> for qualified     personnel our industry, and there can be <font color="blue">no assurances</font> that we will be able     to attract and retain the qualified personnel <font color="blue">necessary</font> for the growth of     our business</td>
    </tr>
    <tr>
      <td>Anti-takeover  provisions  in  our <font color="blue">Amended and Restated Certificate </font>of     <font color="blue">In<font color="blue">corporation</font> </font>and Amended and Restated By-Laws, and certain provisions of     <font color="blue">Delaware </font><font color="blue">law could prevent</font> or <font color="blue">delay <font color="blue"><font color="blue">transaction</font>s</font></font> that our <font color="blue">stockholders</font> may     favor</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our <font color="blue">Amended and Restated Certificate </font>of <font color="blue">In<font color="blue">corporation</font> </font>    and Amended and Restated By-Laws may discourage, delay or prevent a merger     or <font color="blue">acquisition</font> that our <font color="blue">stockholders</font> may consider favorable, including     <font color="blue"><font color="blue">transaction</font>s</font> in which our <font color="blue">stockholders</font> might otherwise receive a premium for     their shares</td>
    </tr>
    <tr>
      <td>For example, these provisions:          •                 authorize the issuance of  &amp;quote blank check &amp;quote  <font color="blue">preferred stock without</font>                 any need for action by <font color="blue">stockholders</font>;          •                 provide for a classified <font color="blue">Board of <font color="blue">Directors </font></font><font color="blue">with staggered</font>                 three-year terms (however, our <font color="blue">Board of <font color="blue">Directors </font></font>has submitted                 a proposal to amend our <font color="blue">Amended and Restated Certificate </font>of                 <font color="blue">In<font color="blue">corporation</font> </font>to eliminate the classification <font color="blue">of the Board </font>of                 <font color="blue"><font color="blue">Directors </font> </font>for stockholder approval during our 2006 Annual                 Meeting of Stockholders);          •                 require <font color="blue">supermajority stockholder approval</font> to effect various                 <font color="blue">amendments</font> to our charter and by-laws;          •                 eliminate the ability of <font color="blue">stockholders</font> to <font color="blue">call special meetings</font>                 of <font color="blue">stockholders</font>;          •                 <font color="blue">prohibit stockholder action by written consent</font>; and          •                 establish  advance notice <font color="blue">requirements</font> for <font color="blue">nominations</font> for                 election to the board of <font color="blue">directors</font> or for <font color="blue">proposing matters</font> that                 can be acted on by <font color="blue">stockholders</font> at stockholder meetings</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> has adopted a <font color="blue">stockholder rights</font>     plan intended to protect <font color="blue">stockholders</font> in the event of an unfair or coercive     offer to acquire our Company and to provide our board of <font color="blue">directors</font> with     adequate time to <font color="blue">evaluate unsolicited offers</font></td>
    </tr>
    <tr>
      <td>This rights plan may have     anti-takeover effects</td>
    </tr>
    <tr>
      <td>The rights plan would cause substantial dilution to a     person or group that attempts to acquire us on terms that our board of     <font color="blue">directors</font>  does  not  believe  are in the <font color="blue">best interests</font> of us and our     <font color="blue">stockholders</font> and may discourage, delay or prevent a merger or <font color="blue">acquisition</font>     that <font color="blue">stockholders</font> may consider favorable, including <font color="blue"><font color="blue">transaction</font>s</font> in which     our <font color="blue">stockholders</font> might otherwise receive a premium for their shares</td>
    </tr>
    <tr>
      <td>As a <font color="blue">Delaware </font><font color="blue">corporation</font>, we are also subject to certain <font color="blue">Delaware </font>    anti-takeover provisions</td>
    </tr>
    <tr>
      <td>Under <font color="blue">Delaware </font>law, a <font color="blue">corporation</font> may not engage     in a business <font color="blue">combination with</font> any holder of 15prca or more of its capital     stock unless the holder has held the stock for <font color="blue">three years</font> or, among other     things, the board of <font color="blue">directors</font> has approved the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Our Board of     <font color="blue">Directors </font><font color="blue">could rely on</font> <font color="blue">Delaware </font>law to prevent or delay an <font color="blue">acquisition</font> of     us</td>
    </tr>
  </tbody>
</table>